This is a public record generated listing.
Assets of Clinical Stage Biopharmaceutical Company
Listing Information
Attachments
Assets of Clinical Stage Biopharmaceutical Company
Price: $10,250,169.60
Other Item Info
Item #: njbke_1036714
Created: 03/19/2019
Category: Business Property > All Assets or Going Concerns > Pharmaceuticals & Biotechnology
Sale Date: None Set
Created: 03/19/2019
Category: Business Property > All Assets or Going Concerns > Pharmaceuticals & Biotechnology
Sale Date: None Set
Seller Info
Morris S. Bauer
Debtor's Attorney
PO Box 5933
Bridgewater, NJ 08807
(908) 722-0700
Debtor's Attorney
PO Box 5933
Bridgewater, NJ 08807
(908) 722-0700
Bankruptcy Info
Case #: 2:19-bk-13273
Case Title: Immune Pharmaceuticals Inc.
Court: New Jersey Bankruptcy Court
Chapter: 11
View Case Docket
Case Title: Immune Pharmaceuticals Inc.
Court: New Jersey Bankruptcy Court
Chapter: 11
View Case Docket
Description
Sale of the Ceplene® Product Line of Immune Pharmaceuticals Inc (Seller's), including marketing authorizations, intellectual property, permits, licenses, and all of the Immune Seller's rights in all issued and outstanding shares of capital stock of Cytovia International Sari and other assets (collectively the "Ceplene Assets").
Ceplene® is a cancer drug approved (though with minimal sales) in the European Union for the maintenance of remissions in patients with Acute Myeloid Leukemia in combination with interleukin 2 and two vascular disrupting agents.
Ceplene Assets for sale is more particularly described in "Exhibit A" from Page No. 29-34 on the attached PDF.
Financial Overview
Income and Expenses ($)
months
Revenue/Gross Income:
Total Expenses:
Cash Flow:
Asset and Liability Summary ($)
Receivables:
Inventory:
FF&E:
Real Estate:
Total Assets:
Liabilities to assume: